FinanceCalifornia's New Transparency Law Reveals Steep Rise In Wholesale Drug Prices
Generic drugs saw the largest median increase of 37.6% from 2017 through the first quarter of 2019.
StrategyHHS OIG: Medicare Part D Drug Rebates 'Substantially' Reduced Spending Growth
Between 2011 and 2015, rebates for brand-name prescription drugs still increased $2 billion.
StrategyThe Return on Investing in Elder Care
The business case for age-friendly health systems offers push to standardize best practices.
Judge Cites Opioid 'Menace,' Awards Oklahoma $572M In Landmark Case
It's the first ruling to hold a pharmaceutical company responsible for one of the worst drug epidemics in American history....
Clinical CareEPA Ban on Sewering Hazardous Waste Drugs Takes Effect Wednesday
The sewering ban, one of the more stringent changes outlined in EPA's rule, is the only part of the rule...
StrategyDrugmakers Master Rolling Out Their Own Generics To Stifle Competition
Critics say authorized generics hurt long-term competition and often perversely increase costs, even in the short term.
StrategyAzar Outlines Drug Importation Plan After Reversing His Position
The breadth of the plan's impact will depend in large part on proposals brought forward by the industry.
Clinical CareCommon Medications Can Masquerade As Dementia In Seniors
Older adults are highly susceptible to negative responses anticholinergic drugs?a wide-ranging class of medications.
Trump Has Blessed States' Exploration Of Importing Drugs. Will It Catch On?
The states' plans signal how frustration among consumers is putting pressure on federal and state officials.
FinanceTrump Issues Executive Order on Healthcare Price Transparency
Officials say the move will result in lower healthcare costs by unleashing competition. Some industry stakeholders are disputing that claim.
Clinical Care'Unprecedented' Survival Benefit Vanishes in Confirmatory Cancer Trial
Over $1 billion in sales for drug possibly without benefit.
StrategyTransparency Bills May Have Unintended Consequences
Lawmakers hear concerns about provisions on drug samples, price increases.